In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...

Buying medicines can get confusing because the same tablet or syrup is often sold under different names and prices. Medicines come in two main forms: branded drugs and generic drugs. A branded drug is ...

Pacira BioSciences faces significant risk as generic challenges threaten Exparel, its flagship product responsible for 78% of 2024 revenue. PCRX's complex formulation, robust patent estate, and ...

This annual observance highlights the importance of generic medicines in providing affordable, effective and accessible healthcare to Filipinos. It was held under the theme “Ginhawang Generics, Ramdam ...

The settlement agreement will extend market exclusivity for AbbVie’s JAK inhibitor in the U.S. until 2037—providing pediatric exclusivity is granted. AbbVie has reached a settlement with generic ...

With Rinvoq and its sibling medicine Skyrizi having successfully picked up the sales torch in the wake of Humira’s tumble over the patent cliff, AbbVie is working to cover its legal bases so the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. For the first time, a generic GLP-1 has been approved by ...

Medications are rarely made from start to finish in a single country; raw materials, active ingredients and final products often cross multiple borders before reaching patients in the U.S., The New ...

Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. America’s generic drug market is one of our greatest health ...

Sun Pharmaceutical and its Taro Pharmaceutical subsidiary are washing their hands of another segment of a years-long antitrust debacle with a $200 million settlement. The deal will clear all claims ...

Sun Pharmaceutical Industries Ltd. settled claims worth $200 million in an antitrust case in Pennsylvania alleging that the firm, along with others, colluded to fix prices of generic drugs. The units ...